CD8A and neoplasm: Additionally, we found the expression levels of key markers in two anti-tumor pathways associated with CD8+ T cells, IFN-γ pathway (St Paul and Ohashi 2020) and m6A pathway (Wang et al. 2020) in two risk groups indicating that the ERS-related signature was closely associated with the response to immunotherapy.